Treatment Experiences for Patients Receiving Buprenorphine/Naloxone for Opioid Use Disorder: A Qualitative Study of Patients’ Perceptions and Attitudes-Reference-Cited by-同舟云学术

Treatment Experiences for Patients Receiving Buprenorphine/Naloxone for Opioid Use Disorder: A Qualitative Study of Patients’ Perceptions and Attitudes

Published:2023-02-10 Issue:4 Volume:58 Page:512-519
ISSN:1082-6084
Container-title:Substance Use & Misuse
language:en
Short-container-title:Substance Use & Misuse

Author:

Young Gary J.¹²³,Hasan Md Mahmudul⁴⁵⁶,Young Leonard D.⁷,Noor-E-Alam Md.¹⁸^ORCID

Affiliation:

1. Center for Health Policy and Healthcare Research, Northeastern University, Boston, Massachusetts, USA

2. Bouve College of Health Sciences, Northeastern University, Boston, Massachusetts, USA

3. D’Amore-Mckim School of Business, Northeastern University, Boston, Massachusetts, USA

4. Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, Florida, USA

5. Department of Information Systems and Operations Management, College of Business, University of Florida, Gainesville, USA

6. Center for Drug Evaluation and Safety, University of Florida, Gainesville, Florida, USA

7. Prescription Monitoring Program, Massachusetts Department of Public Health, Boston, Massachusetts, USA

8. Department of Mechanical and Industrial Engineering, Northeastern University, Boston, Massachusetts, USA

Funder

Massachusetts Department of Public Health

Centers for Disease Control and Prevention

Publisher

Informa UK Limited

Subject

Psychiatry and Mental health,Public Health, Environmental and Occupational Health,Medicine (miscellaneous),Health (social science)

Link

https://www.tandfonline.com/doi/pdf/10.1080/10826084.2023.2177111

Reference40 articles.

1. Ahrnsbrak, R., Bose, J., Hedden, S. L., Lipari, R. N. & Park-Lee, E. (2017).Key substance use and mental health indicators in the United States: Results from the 2016 National Survey on Drug Use and Health. (HHS Publication No. SMA 17-5044, NSDUH Series H-52). Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration.

2. American Psychiatric Association. (2021).Opioid use disorder. https://www.psychiatry.org/patients-families/addiction/opioid-use-disorder

3. Comparison of costs and utilization among buprenorphine and methadone patients

4. Societal Costs of Prescription Opioid Abuse, Dependence, and Misuse in the United States

5. Centers for Disease Control and Prevention (2021).Suspected nonfatal drug overdoses during COVID-19. https://www.cdc.gov/drugoverdose/nonfatal/states/covid-19.html

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Endogenous opiates and behavior: 2023;Peptides;2024-09

2. Patients' Perspectives on Discontinuing Buprenorphine for the Treatment of Opioid Use Disorder;Journal of Addiction Medicine;2024-03-18

3. An Assessment of the One-Month Effectiveness of Telehealth Treatment for Opioid Use Disorder Using the Brief Addiction Monitor;Substance Use & Addiction Journal;2023-12-29